Join our daily newsletter At The Bell to receive exclusive market insights
- Bupa UK Insurance becomes the first health insurance company to provide reimbursement for OncoSil Medical’s (OSL) namesake device
- Following this milestone, OncoSil will be working with the London Clinic to provide reimbursement with other health insurers in the UK
- The OncoSil device implants a pre-determined dose of beta radiation directly into cancerous tissue via endoscopic ultrasound guidance
- This helps locate the cancerous cells while chemotherapy is then used to destroy them
- Shares in OncoSil are up 35 per cent on the market and were trading at 5.4 cents at 12:06 pm AEST
Bupa UK Insurance has become the first health insurance company to provide reimbursement for OncoSil Medical’s (OSL) namesake device.
Following this milestone, OncoSil will be working with the London Clinic to provide reimbursement with other health insurers in the UK.
OncoSil’s namesake device is a brachytherapy (cancer treatment) device that implants a pre-determined dose of beta radiation directly into the cancerous tissue via injection under endoscopic ultrasound guidance.
The ultrasound then uses high-frequency sound waves to produce detailed images of the lining and walls of specific organs, with the beta particles travelling a short distance to the tissue causing the damage.
The procedure helps locate the cancerous cells and then chemotherapy destroys them.
“With a leading health insurer agreeing to reimburse the OncoSil device, this allows patients with locally advanced pancreatic cancer access to this breakthrough treatment at The London Clinic,” CEO and Managing Director Nigel Lange said.
“We look forward to working with other institutions in the United Kingdom and additional private insurers to make the OncoSil device even more accessible to all patients who may benefit from this novel treatment.”
Shares in OncoSil were up 35 per cent on the market and were trading at 5.4 cents at 12:06 pm AEST.
